A French health agency has launched a temporary scientific committee to assess how to create a medical cannabis market in France.
The French National Agency for the Safety of Medicines and Health Products (ANSM) has tasked the committee with:
- Evaluating scientific data related to medical cannabis.
- Assessing the experiences of other countries that have implemented such a program.
- Considering patient experiences and feedback in other markets.
The committee will assess the feasibility of creating an MMJ market, which medical conditions it should be allowed for and how such a market would be accessed.
The committee, whose members are expected to be chosen soon, is expected to provide its first conclusions by the end of the year.